UK markets open in 3 hours 18 minutes

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
895.00-5.60 (-0.62%)
At close: 04:59PM CET
Full screen
Previous close900.60
Open895.00
Bid892.30 x 0
Ask892.90 x 0
Day's range889.70 - 902.50
52-week range604.40 - 902.50
Volume1,286,181
Avg. volume1,560,068
Market cap2.005T
Beta (5Y monthly)0.34
PE ratio (TTM)38.61
EPS (TTM)23.18
Earnings date01 Feb 2023
Forward dividend & yield11.15 (1.24%)
Ex-dividend date12 Aug 2022
1y target est875.18
  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 5 December 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme

  • Zacks

    Beat the Market Like Zacks: Novo Nordisk, Axon, General Mills in Focus

    Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

  • Zacks

    Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia

    The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.